Source: Pharmacy Times articles
New data reveals isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma.
by MM360 Staff | Jul 9, 2025 | Myeloma News | 0 comments
Source: Pharmacy Times articles
New data reveals isatuximab-based therapy achieves high MRD-negativity rates in newly diagnosed multiple myeloma.